• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Verve Therapeutics Inc.

    4/29/25 4:01:45 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Verve Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    92539P101

    (CUSIP Number)


    04/22/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92539P101


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,327,227.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,327,227.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,327,227.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    92539P101


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,327,227.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,327,227.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,327,227.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    92539P101


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,327,227.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,327,227.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,327,227.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Verve Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    201 Brookline Avenue, Suite 601, Boston, Massachusetts 02215
    Item 2. 
    (a)Name of person filing:

    Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    92539P101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page. After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on April 22, 2025, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:04/28/2025
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:04/28/2025
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:04/28/2025
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of April 28, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $VERV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERV

    DatePrice TargetRatingAnalyst
    4/15/2025Neutral → Overweight
    Cantor Fitzgerald
    4/8/2024$15.00Buy
    H.C. Wainwright
    4/13/2023$29.00Buy
    Canaccord Genuity
    2/1/2023$21.00Neutral
    Cantor Fitzgerald
    12/15/2022$13.00Sell
    Goldman
    10/6/2022$48.00Neutral
    Credit Suisse
    8/25/2022$32.00 → $56.00Hold → Buy
    Stifel
    6/17/2022$48.00Outperform
    BMO Capital Markets
    More analyst ratings

    $VERV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

      Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress with a program update expected in the second half of 2025 Cash, cash equivalents, and marketable securities of approximately $500 million; cash runway into mid-2027 BOSTON , May 14, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic med

      5/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 134,860 shares of the company's common stock and an aggregate of 65,398 restricted stock units (RSUs). The options have an exercise price of $5.67 per share, which is equa

      5/2/25 4:05:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

      Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

      4/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Financials

    Live finance-specific insights

    See more
    • Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

      Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

      4/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

      LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans to Initiate Expansion Cohort in 2024 Company to Host Conference Call and Webcast Today at 6:30 p.m. ET BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing hear

      11/12/23 3:30:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Verve Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Verve Therapeutics from Neutral to Overweight

      4/15/25 8:57:58 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Verve Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $15.00

      4/8/24 8:03:41 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Verve Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $29.00

      4/13/23 7:37:44 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Verve Therapeutics Inc.

      SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/18/24 5:23:52 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

      SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/12/24 5:52:40 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

      SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/4/24 1:52:43 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

      BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi

      9/18/23 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. "Bo" Cumbo, to its Board of Directors

      CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory

      6/13/22 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Administrative Officer Nickerson Joan converted options into 9,315 shares and sold $11,525 worth of shares (2,777 units at $4.15), increasing direct ownership by 60% to 17,420 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:17 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Ashe Andrew D. converted options into 9,000 shares and sold $11,126 worth of shares (2,681 units at $4.15), increasing direct ownership by 2% to 348,828 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:14 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kathiresan Sekar converted options into 33,000 shares and sold $40,761 worth of shares (9,822 units at $4.15), increasing direct ownership by 7% to 346,686 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:19 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    SEC Filings

    See more
    • SEC Form EFFECT filed by Verve Therapeutics Inc.

      EFFECT - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/15/25 12:15:05 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Verve Therapeutics Inc.

      10-Q - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/14/25 7:30:21 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/14/25 7:15:09 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ashe Andrew D. bought $475,760 worth of shares (76,000 units at $6.26), increasing direct ownership by 29% to 342,509 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      5/15/24 5:30:07 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yeshwant Krishna bought $18,000,000 worth of shares (1,800,000 units at $10.00) (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      12/5/23 4:30:09 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care